Is IRMD Stock Undervalued?

A comprehensive valuation analysis of Iradimed Corp (IRMD) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated April 16, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

255638516.4% upside potential

Based on our analysis, Iradimed Corp appears to be potentially undervalued at the current price of $93.05. Our fair value estimate of $237871732.56 suggests upside potential of approximately 255638516.4%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing IRMD relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

53.46

High

P/B Ratio

12.64

High

P/S Ratio

14.27

High

EV/EBITDA

41.91

High

Understanding the Metrics

P/E Ratio: At 53.46x earnings, IRMD is trading above the typical market average of 15-20x.
P/B Ratio: A P/B of 12.64 means investors pay $12.64 for every $1 of book value.
P/S Ratio: The price-to-sales ratio of 14.27 indicates how much investors value each dollar of revenue.
EV/EBITDA: This ratio of 41.91 helps compare IRMD to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Iradimed Corp stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$93.05

Fair Value Estimate

$237871732.56

Implied Return+255638516.4%

Our DCF model suggests IRMD may be undervalued by approximately 255638516.4%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Analyst Price Targets

Wall Street analysts provide price targets based on their fundamental research and models. Let's see how the consensus view compares to the current price.

Current Price

$93.05

→

Analyst Target

$118.67

Implied Upside27.5%

The consensus analyst price target of $118.67 suggests 27.5% upside potential from current levels. Analysts appear optimistic about the stock's prospects.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Iradimed Corp (IRMD) appears to be undervalued at $93.05. With a fair value estimate of $237871732.56, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.